SCN5A and atrial fibrillation: The present study reported a single case and did not evaluate the prevalence of BrS in a large cohort of AF patients harboring SCN5A after PIP treatment, while our results provided an evidence of R1193Q enhanced the sensitivity to propafenone, further clinical and epidemiological studies are warranted.